CJ Bioscience to Unveil Groundbreaking Data on Inflammatory Bowel Disease Treatment at ECCO 2025 At ECCO 2025, CJ Bioscience will share preclinical findings for CJRB-201, targeting inflammatory bowel disease, with clinical trials set for 2026.

CJ Bioscience to Unveil Groundbreaking Data on Inflammatory Bowel Disease Treatment at ECCO 2025 #South_Korea #Seoul #CJ_Bioscience #CJRB-201 #Inflammatory_Bowel

CJ Bioscience Unveils Promising Data for IBD Drug Candidate CJRB-201 at ECCO 2025 Discover groundbreaking preclinical findings from CJ Bioscience on its drug candidate CJRB-201, targeting chronic inflammatory bowel diseases with a potential clinical launch in 2026.

CJ Bioscience Unveils Promising Data for IBD Drug Candidate CJRB-201 at ECCO 2025 #South_Korea #Seoul #IBD #CJ_Bioscience #CJRB-201

CJ Bioscience Set to Unveil Innovative Gut Health Treatment at ECCO 2025 Conference Revolutionizing IBD treatment, CJ Bioscience will showcase preclinical findings on CJRB-201, an innovative solution for gut health issues, in Berlin.

CJ Bioscience Set to Unveil Innovative Gut Health Treatment at ECCO 2025 Conference #None #Berlin #Inflammatory_Bowel_Disease #CJ_Bioscience #CJRB-201

CJ Bioscience to Showcase Promising Preclinical Data at ECCO 2025 Related to CJRB-201 for IBD Treatment CJ Bioscience will present CJRB-201's preclinical data at ECCO 2025, targeting inflammatory bowel disease with a novel formulation aiming for clinical trials in 2026.

CJ Bioscience to Showcase Promising Preclinical Data at ECCO 2025 Related to CJRB-201 for IBD Treatment #South_Korea #Seoul #IBD_treatment #CJ_Bioscience #CJRB-201